Open Access Macedonian Journal of Medical Sciences. 2018 January 07.
Nicola Zerbinati, Torello Lotti, Damiano Monticelli, Raffaele Rauso, Pablo González–Isaza, Edoardo D’Este, Alberto Calligaro, SabrinaSommatis, Cristina Maccario, Roberto Mocchi, Jacopo Lotti, Uwe Wollina, Georgi Tchernev, Katlein França
OBJECTIVE: NeauviaStimulate is biocompatible, injectable hyaluronic acid (HA) filler (26 mg/ml) PEG cross-linked with 1% of calcium hydroxyapatite (CaHA) for facial soft-tissue augmentation that provides volume to tissues, followed by process ofneocollagenesisfor improving skin quality.
AIM: The aim of the present study isto evaluate the biosafety of the product (Lot. 160517-26-1/2 PEG) on human keratinocytes cultured in vitro.
MATERIAL AND METHOD: The experimental model proposed, despite being an in vitro system, allows the derivation of useful information to predict the possible activity of the product in further in vivo application. Human keratinocytes (HaCaT cells) were treated with the product for 24h at increasing concentrations of product respect to control (untreated cells).
RESULTS: The biosafety of the product to be tested has been evaluatedperforming different methods: MTT test, NRU test, Kenacid Blue assay. Moreover, any possible effect on the structure, morphology, and viability of cells has been evaluated.
CONCLUSIONS: In conclusion, the results obtained by the different methods show that the product Neauvia Stimulate® does not cause any cytotoxic effect and does not affect the correct structure and morphology of cells cultures.